UBS lowers Myriad Genetics price target to $3.6, keeps Neutral
- UBS analyst Lu Li cuts Myriad Genetics price target from $6 to $3.6
- Rating remains Neutral on NASDAQ: MYGN
- Target reduction represents a 40% decrease in upside estimate
*this image is generated using AI for illustrative purposes only.
UBS analyst Lu Li has lowered the price target for Myriad Genetics (NASDAQ: MYGN) from $6 to $3.6. The firm maintains its Neutral rating on the stock.
The adjustment reflects a significant reduction in the upside potential previously priced into the equity. The new target implies a steeper discount relative to prior valuations, though the Neutral stance suggests the current market price may still align with fundamental expectations.
| Metric | Previous | New |
|---|---|---|
| Price Target | $6 | $3.6 |
| Rating | Neutral | Neutral |
What the Numbers Show
The 40% reduction in the price target ($2.4 drop) signals a material reassessment of future value drivers by UBS. Despite the cut, the retention of the Neutral rating indicates that the analyst does not view the stock as overvalued at current levels, but rather sees limited immediate upside catalysts.
What specific changes in Myriad Genetics' financial projections or market assumptions led UBS to reduce the price target by 40% while maintaining a Neutral rating?
How does the new $3.6 price target compare to Myriad Genetics' current trading price, and what does this imply about near-term volatility?
Are there upcoming clinical trial results or regulatory decisions for Myriad's non-Cancer products that could serve as potential upside catalysts?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
